The EU Commission accepts commitments from pharmaceutical company to address excessive pricing (Aspen)

On 10 February 2021, the European Commission accepted commitments from Aspen under Article 9(1) of Regulation 1/2003, concluding a three year investigation into suspected excessive pricing practices affecting six critical cancer medicines. What you need to know - key takeawaysThe Commission based its assessment of pricing levels on the absolute and relative profitability of the medicines; considering Aspen's costs as well as profit levels of other similar businesses in the pharmaceutical industry.The Commission also considered the lack of potential justifications for price and profit levels; in this case

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Ashurst (Brussels)

Quotation

Donald Slater, The EU Commission accepts commitments from pharmaceutical company to address excessive pricing (Aspen), 10 February 2021, e-Competitions February 2021, Art. N° 99613

Visites 36

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues